CDC director slams agency's response to COVID-19 pandemic

Rochelle P. Walensky, MD, MPH, director of the Centers for Disease Control and Prevention (CDC), slammed the agency for failing to respond to the COVID-19 pandemic quickly enough, according to a report from The New York Times.

Her remarks came during a senior staff meeting Aug. 17, with Walensky, formerly chief of the Division of Infectious Diseases at Massachusetts General Hospital and professor of medicine at Harvard Medical School, outlining a broad plan to reorganize the agency to meet public health needs and prevent future outbreaks. Facing heavy criticism for the CDC’s COVID-19 response, Walensky ordered an external review of the agency in April. Her message this week offered an unspecific plan to overhaul the CDC, released in a video to all CDC employees. 

“For 75 years, CDC. and public health have been preparing for Covid-19, and in our big moment, our performance did not reliably meet expectations,” she said Wednesday. “My goal is a new, public health, action-oriented culture at CDC that emphasizes accountability, collaboration, communication and timeliness.” 

Among the changes, Walensky announced the appointment of Mary K. Wakefield, a former Obama administration health official who will lead the CDC’s shift to a stronger public health focus, the NY Times reported. 

Walensky’s plan comes as the CDC is dealing with outbreaks of two other infectious diseases causing concern––monkeypox and polio.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The American College of Cardiology has sent a letter to HHS Secretary Robert F. Kennedy Jr. that outlines some of the organization’s central priorities and concerns. 

One product is being pulled from the market, and the other is receiving updated instructions for use.

If the Trump administration continues taking a laissez-faire stance toward AI—including AI used in healthcare—why not let the states go it alone on regulating the technology?